OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	273
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	178
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	95
Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice	70
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	64
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	61
Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	58
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C _H 1-C _λ interfac	51
HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	47
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms	40
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	37
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering	36
Development of T-cell engagers selective for cells co-expressing two antigens	33
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies	32
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	31
Engineering death resistance in CHO cells for improved perfusion culture	31
In silico prediction of post-translational modifications in therapeutic antibodies	29
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	28
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties	28
In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom	27
A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation	27
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	26
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	25
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4 ⁺ T cell interl	24
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	23

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	22
Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation	21
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	21
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	20
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody	20
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	20
Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation	20
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	20
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches	20
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	20
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	19
Correction	19
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	19
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	19
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	17
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy	16
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody	16
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	16
Modulation of the high concentration viscosity of IgG ₁ antibodies using clinically validated Fc mutations	15
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	15
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	14
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	14
Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development	13
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches	13
Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2	13
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	13
Predicting purification process fit of monoclonal antibodies using machine learning	13
Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study	13
Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana	13
Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies	13
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method	12
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies	12
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	12
“Stapling” scFv for multispecific biotherapeutics of superior properties	12
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	12
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT	12
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	11
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	11
Investigating protein–excipient interactions of a multivalent V _HH therapeutic protein using NMR spectroscopy	11
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning	11
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	10
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing	10
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants	10
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics	10
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	10
The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa	10
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing	9
Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model	9
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic	9
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	8

Assessing developability early in the discovery process for novel biologics	8
Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring	8
Correction	8
Improved therapeutic index of an acidic pH-selective antibody	8
Biparatopic antibodies: therapeutic applications and prospects	8
Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate	8
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	8
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras	8